Several studies discussed the beneficial effects of the GLP1 (EECs product) agonists on metabolic disorders in schizophrenia patients [74], while others also revealed the potential neuroprotective effect of GLP1 agonists [75,76]. This evidence concerns the gene GCG and schizophrenia.